Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: A comparison to other 5-HT receptor subtypes

Psychopharmacology

Volumn 168, Issue 4, 2003, Pages 397-409

  Millan, Mark J ^a   Veiga, Sylvie ^a   Girardon, Sylvie ^a   Brocco, Mauricette ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT 1B; 5 HT2A; Antidepressant; Citalopram; Locomotion; MDL100,907; SB224,289; Serotonin (5 HT); SSRI

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CITALOPRAM; DRUG VEHICLE; EPLIVANSERIN; FLUVOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 3 METHYL 4 (4 PYRIDYL)BENZAMIDE; ONDANSETRON; S 18127; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TOCRIS; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CITALOPRAM; ENVIRONMENT DESIGN; FLUVOXAMINE; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MOTOR ACTIVITY; MOVEMENT DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0041508687     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1389-y     Document Type: Article

References (129)

1. 35S]-GTPγS binding isotherms. Neuropharmacology 40:57-64
2. 1A receptor antagonist WAY100,635. Int J Neuropsychopharmacol 4:399-408
3. Bankson MG, Cunningham KA (2002a) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846-852
4. 2 receptors. Neuropsychopharmacology 26:40-52
5. Barker EL, Blakely RD (1995) Norepinephrine and serotonin transporters: molecular targets for antidepressant drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation in progress. Raven Press, New York, pp 321-334
6. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152
7. 1B receptor knock-out mice. Pharmacol Biochem Behav 66:221-225
8. 6 receptors in nigro-striatal function in rodents. Br J Pharmacol 125:1562-1566
9. 2 receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J Neurochem 75:1625-1633
10. 1A receptor antagonist, WAY100,635, in the rat. Neuropharmacology 39:1222-1236
11. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002) Induction of locomotion in mice exposed to a novel environment by inhibition of serotonin reuptake a pharmacological characterization of diverse classes of antidepressant agent. Pharmacol Biochem Behav 71:667-680
12. 1B knockout mice: effects of injection route on acute and sensitized responses. Behav Pharmacol 12:549-555
13. 1B binding sites in rat brain. Naunyn-Schmiedelberg's Arch Pharmacol 347:569-582
14. Caldecott-Hazard S, Morgan DG, DeLeon-Jones F, Overstreet DH, Janowsky D (1991) Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse 9:251-301
15. Caligiuri MP, Ellwanger J (2000) Motor and cognitive aspects of motor retardation in depression. J Affect Disord 57:83-93
16. 1B agonist. J Pharmacol Exp Ther 263:318-326
17. 1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7:113-127
18. Chaouloff F, Courvoisier H, Moisan MP, Mormède P (1999) GR127935 reduces basal locomotor activity and prevents RU24969 but not D-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Psychopharmacology 141:326-331
19. 1B receptor. Br J Pharmacol 110:1621-1629
20. 7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem 71:1271-1279
21. 2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 11:145-152
22. 1B receptors. J Pharmacol Exp Ther 277:823-830
23. 3H]phosphatidylinositols. Naunyn-Schmiedeberg's Arch Pharmacol 365:242-252
24. 1d autoreceptors. Br J Pharmacol 114:1107-1109
25. 1B receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo. J Neurochem 75:213-2122
26. 6 receptor antagonist SB271,046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25:662-668
27. 2C receptors. Trends Pharmacol Sci 22:502-503
28. 4 receptors indirectly enhances in vivo dopamine release in the rat striatum. J Neurochem 68:195-203
29. 3 receptors. J Neurosci 18:6528-6538
30. 2C receptor agonist, RO 60-0175: a pharmacological analysis. Neuropharmacology 38:415-423
31. 2C receptors. Neuropharmacology 39:1114-1117
32. 1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. J Pharmacol Exp Ther 292:610-617
33. 2C receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229-232
34. 1A receptor knockout mice, show reduced startle reactivity and footshock-induced sensitization, as measured with the acoustic startle response. Behav Brain Res 118:169-178
35. 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864:176-185
36. 1B/1D receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 356:328-334
37. 2B receptors in the medial amydgala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 36:601-608
38. 1B knock-out mice. Eur J Neurosci 11:3823-3831
39. 1B receptors in the nucleus accumbens reduces amphetamine-induced enhancement of responding for conditioned reward. Psychopharmacology 142:165-174
40. 1A receptor antagonist. Behav Brain Res 73:337-353
41. Fletcher PJ, Korth KM, Robinson SR, Baker GB (2002) Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology 162:282-291
42. 4 receptor ligands in rat spatial navigation. Neuropharmacology 4/5:689-696
43. 1B receptor inverse agonist 1′-methyl-5-[[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]-2,3,6,7-tetrahydro-spiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem 41:1218-1235
44. 6 receptor-like material in the rat central nervous system. Brain Res 746:207-219
45. Geyer MA (1996) Serotonergic functions in arousal and motor activity. Behav Brain Res 73:31-36
46. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84:413-429
47. Gobert A, Dekeyne A, Millan MJ (2000a) The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology 39:1608-1616
48. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205-221
49. Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology. J Psychopharmacol 12:S5-S20
50. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793-802
51. 2 cortical regions. Biol Signals 3:223-229
52. 7 receptor antagonist. Br J Pharmacol 130:539-548
53. 1B/1D agonist. Psychopharmacology 141:242-250
54. Herges S, Taylor DA (1998) Involvement of serotonin in the modulation of cocaine-induced locomotor activity in the rat. Pharmacol Biochem Behav 59:595-611
55. Hillegaart V (1990) Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on motor activity in the rat. Physiol Behav 48:143-148
56. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223-226
57. B synaptic potential in rat dopamine neurons. J Neurosci 12:2000-2006
58. 3 receptor antagonist. Br J Pharmacol 93:985-993
59. Kalkman HO, Soar J (1990) Determination of the 5-HT receptor subtype involved in 8-OH-DPAT induced hyperlocomotion potential difficulties arising from inadequate pharmacological tools. Eur J Pharmacol 191:383-390
60. 3 receptor antagonist MDL 72222 attenuates cocaine-and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology 159:341-350
61. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427-434
62. 2C receptor antagonist. Neuropharmacology 36:609-620
63. 1B receptors in different brain regions of the mouse. J Pharmacol Exp Ther 298:1083-1091
64. 4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function. Eur J Neurosci 13:889-898
65. Lucki I, Ward HR, Frazer A (1989) Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249:155-164
66. Maes M, Meltzer HY (1995) The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation in progress. Raven Press, New York, pp 933-944
67. 1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. J Neurosci 19:6757-6168
68. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924
69. 1B receptor mutant mice. J Pharmacol Exp Ther 298:1101-1107
70. 1B/1D receptors. J Pharmacol Exp Ther 290:965-973
71. 4 receptors in the nucleus accumbens shell. J Pharmacol Exp Ther 291:300-307
72. 2A receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 297:357-363
73. 2B/2C receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology 24:319-329
74. Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591-613
75. Meneses A (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23:1111-1125
76. 1A receptors. J Pharmacol Exp Ther 295:853-861
77. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355-474
78. 2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325:9-12
79. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432
80. 2C receptors are involved in the discriminative stimulus effects of citalopram in rats. Psychopharmacology 142:432-434
81. 1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology 21:61S-67S
82. Millan MJ, Lejeune F, Gobert A (2000) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14:114-138
83. Millan MJ, Dekeyne A, Papp M, Drieu La Rochelle C, MacSweeny C, Peglion JL, Brocco M (2001a) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioural profile in comparison to venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 298:581-591
84. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001b) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological and neurochemical profile in comparison to venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 298:565-580
85. 3H]GR125,743 a pharmacological characterization. Pharmacol Biochem Behav 71:589-598
86. 1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology 98:321-329
87. 2A Receptors mediate pergolide-induced hyperactivity. Behav Pharmacol 10:S63
88. 1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404:1-12
89. 1B auto- and heteroceptors. Mol Pharmacol 58:1273-1278
90. 1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats. Eur J Pharmacol 372:127-134
91. 2A receptors in the discriminative-stimulus effects of cocaine and methamphetamine. Eur J Pharmacol 436:75-82
92. 7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J Chem Neuroanat 21:63-73
93. 1B receptor/G-protein stoichiometry. Mol Pharmacol 58:1042-1049
94. 2 receptors. J Neurosci Res 55:600-607
95. 1B agonist RU 24969 and effects on dopaminergic behavior. Eur J Pharmacol 139:205-214
96. 3 receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol 10:77-95
97. 1B receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 24:391-398
98. 1B receptors. Psychopharmacology 132:255-260
99. O'Neill MF, Fernandez AG, Palacios JM (1996) GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol Biochem Behav 53:535-539
100. 1B/1D receptor agonist, SKF99101H, induces locomotor hyperactivity in the guinea pig. Eur J Pharmacol 399:49-55
101. 6 receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience 92:1001-1009
102. 2C receptor. Psychopharmacology 126:234-240
103. 1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 32:132-135
104. Paulus MA, Geyer MA (1992) The effects of MDMA and other methylenedioxy-substituted phenalkylamines on the structure of rat locomotor activity. Neuropsychopharmacology 7:15-31
105. Popik P (1999) Preclinical pharmacology of citalopram. J Clin Pharmacol 19:4S-22S
106. 1D receptors. Naunyn-Schmiedeberg's Arch Pharmacol 356:312-320
107. Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 116:1923-1931
108. 1B receptors in the sensitization to amphetamine in mice. Eur J Pharmacol 422:91-99
109. 4 receptor antagonism does not affect motor and reward mechanisms in the rat. Eur J Pharmacol 357:115-120
110. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol 318:213-220
111. 1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8:201-211
112. Reneric JP, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136:190-197
113. 2 receptor antagonist. J Pharmacol Exp Ther 262:759-768
114. Roberts C, Allen L, Langmead CJ, Hagan JJ, Middelmiss DN, Price GW (2001) The effect of SB-269970, a 5-HT receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol 132:1574-1580
115. 6 receptor antagonist. Br J Pharmacol 130:1606-1621
116. Sachdev P, Aniss AM (1994) Slowness of movement in melancholic depression. Biol Psychiatry 35:253-262
117. Sánchez C, Meier E (1997) Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197-205
118. 1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 88:899-915
119. Sasaki-Adams DM, Kelley AE (2001) Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology 25:440-452
120. 1D receptor antagonist. Behav Brain Res 73:157-161
121. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258
122. 6 receptor null mice. Fourth IUPHAR satellite meeting on serotonin, Rotterdam, S1.2
123. 1B receptor and antidepressant effect of selective serotonin reuptake inhibitors. CR Seances Soc Biol Fil 192:1139-1147
124. 3H]GR 125743. Brain Res 915:47-57
125. 1D receptors. Eur J Pharmacol 314:365-372
126. 2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186-199
127. 2 receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. Eur J Pharmacol 427:221-225
128. 1B/1D receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol 418:55-64
129. 2A receptor stimulation in rats pretreated with intermittent cocaine. Brain Res 863:254-258